Publikationen

Sie befinden sich hier:

Publikationen 2016

Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, Loi S.
Clinical relevance of host immunity in breast cancer: from TILs to the clinic.
Nat Rev Clin Oncol. 2016 Apr;13(4):228-41. doi: 10.1038/nrclinonc.2015.215. Epub 2015 Dec 15. Review

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Clin Cancer Res. 2016 Mar 15;22(6):1499-509. doi: 10.1158/1078-0432.CCR-15-1125. Epub 2015 Oct 29.

Taube ET, Denkert C, Sehouli J, Kunze CA, Dietel M, Braicu I, Letsch A, Darb-Esfahani S.
Wilms tumor protein 1 (WT1) - Not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.
Gynecol Oncol. 2016 Mar;140(3):494-502. doi: 10.1016/j.ygyno.2015.12.018. Epub 2015 Dec 22.

Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Darb-Esfahani S, Schmitt WD, Dan Costa S, Gerber B, Engels K, Nekljudova V, Loibl S, von Minckwitz G; German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigator
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
Lancet Oncol. 2016 Mar;17(3):345-56. doi: 10.1016/S1470-2045(15)00542-2. Epub 2016 Feb 8.

Hilvo M, de Santiago I, Gopalacharyulu P, Schmitt WD, Budczies J, Kuhberg M, Dietel M, Aittokallio T, Markowetz F, Denkert C, Sehouli J, Frezza C, Darb-Esfahani S, Braicu EI.
Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas.
Cancer Res. 2016 Feb 15;76(4):796-804. doi: 10.1158/0008-5472.CAN-15-2298. Epub 2015 Dec 18.

Marmé F, Lederer B, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kümmel S, Loibl S, Paepke S, Untch M, von Minckwitz G, Schneeweiss A.
Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy.
Eur J Cancer. 2016 Jan;53:65-74. doi: 10.1016/j.ejca.2015.09.022. Epub 2015 Dec 13.

Publikationen 2015

Budczies J, von Winterfeld M, Klauschen F, Bockmayr M, Lennerz JK, Denkert C, Wolf T, Warth A, Dietel M, Anagnostopoulos I, Weichert W, Wittschieber D, Stenzinger A.
The landscape of metastatic progression patterns across major human cancers.
Oncotarget. 2015 Jan 1;6(1):570-83.

Arsenic R, Treue D, Lehmann A, Hummel M, Dietel M, Denkert C, Budczies J.
Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer.
BMC Clin Pathol. 2015 Nov 18;15:20. doi: 10.1186/s12907-015-0020-6. eCollection 2015.

Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching PA, Pfitzner BM, Gerber B, Gade S, Darb-Esfahani S, Sinn BV, Huober J, Engels K, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, von Minckwitz G.
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy.
Ann Oncol. 2015 Jan;26(1):95-100. doi: 10.1093/annonc/mdu487. Epub 2014 Oct 29.

Fontanella C, Lederer B, Gade S, Vanoppen M, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Schneeweiss A, Paepke S, Jackisch C, Mehta K, Nekljudova V, Untch M, Neven P, von Minckwitz G, Loibl S.
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.
Breast Cancer Res Treat. 2015 Feb;150(1):127-39. doi: 10.1007/s10549-015-3287-5. Epub 2015 Feb 13.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S; International TILs Working Group 2014.
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
Ann Oncol. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11.

Taube ET, Denkert C, Pietzner K, Dietel M, Sehouli J, Darb-Esfahani S.
Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma.
Virchows Arch. 2015 Mar;466(3):333-42. doi: 10.1007/s00428-014-1710-7. Epub 2014 Dec 19.

Denkert C, Pfitzner BM, Heppner BI, Dietel M.
[Molecular pathology for breast cancer: Importance of the gene expression profile].
Pathologe. 2015 Mar;36(2):145-53. doi: 10.1007/s00292-015-0009-z. Review. German.

Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, Schem C, Fisch K, Darb-Esfahani S, Mehta K, Sotiriou C, Wienert S, Klare P, André F, Klauschen F, Blohmer JU, Krappmann K, Schmidt M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Untch M, Loibl S.
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
J Clin Oncol. 2015 Mar 20;33(9):983-91. doi: 10.1200/JCO.2014.58.1967. Epub 2014 Dec 22.

Budczies J, Pfitzner BM, Györffy B, Winzer KJ, Radke C, Dietel M, Fiehn O, Denkert C.
Glutamate enrichment as new diagnostic opportunity in breast cancer.
Int J Cancer. 2015 Apr 1;136(7):1619-28. doi: 10.1002/ijc.29152. Epub 2014 Sep 4.

Ataseven B, Lederer B, Blohmer JU, Denkert C, Gerber B, Heil J, Kühn T, Kümmel S, Rezai M, Loibl S, von Minckwitz G.
Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy.
Ann Surg Oncol. 2015 Apr;22(4):1118-27. doi: 10.1245/s10434-014-4122-7. Epub 2014 Oct 9.

Budczies J, Bockmayr M, Treue D, Klauschen F, Denkert C.
Semiconductor sequencing: how many flows do you need?
Bioinformatics. 2015 Apr 15;31(8):1199-203. doi: 10.1093/bioinformatics/btu805. Epub 2014 Dec 4.

Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S.
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
JAMA Oncol. 2015 Jul;1(4):448-54. doi: 10.1001/jamaoncol.2015.0830. Erratum in: JAMA Oncol. 2015 Jul;1(4):544. JAMA Oncol. 2015 Nov;1(8):1172. Nucifero, Paolo [corrected to Nuciforo, Paolo].

Hanusch C, Schneeweiss A, Loibl S, Untch M, Paepke S, Kümmel S, Jackisch C, Huober J, Hilfrich J, Gerber B, Eidtmann H, Denkert C, Costa S, Blohmer JU, Engels K, Burchardi N, von Minckwitz
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
Clin Cancer Res. 2015 Jul 1;21(13):2924-31. doi: 10.1158/1078-0432.CCR-14-2774. Epub 2015 Mar 30.

Loibl S, Jackisch C, Lederer B, Untch M, Paepke S, Kümmel S, Schneeweiss A, Huober J, Hilfrich J, Hanusch C, Gerber B, Eidtmann H, Denkert C, Costa SD, Blohmer JU, Nekljudova V, Mehta K, von Minckwitz G.
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
Breast Cancer Res Treat. 2015 Jul;152(2):377-87. doi: 10.1007/s10549-015-3479-z. Epub 2015 Jun 25.

Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration.
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
Ann Oncol. 2015 Jul;26(7):1280-91. doi: 10.1093/annonc/mdv161. Epub 2015 May 27. Review.

Sinn M, Riess H, Sinn BV, Stieler JM, Pelzer U, Striefler JK, Oettle H, Bahra M, Denkert C, Bläker H, Lohneis P.
Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
Eur J Cancer. 2015 Aug;51(12):1546-54. doi: 10.1016/j.ejca.2015.05.005. Epub 2015 Jun 3.

Sonnenblick A, Brohée S, Fumagalli D, Vincent D, Venet D, Ignatiadis M, Salgado R, Van den Eynden G, Rothé F, Desmedt C, Neven P, Loibl S, Denkert C, Joensuu H, Loi S, Sirtaine N, Kellokumpu-Lehtinen PL, Piccart M, Sotiriou C.
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.
BMC Med. 2015 Aug 3;13:177. doi: 10.1186/s12916-015-0416-2.

Klauschen F, Wienert S, Schmitt WD, Loibl S, Gerber B, Blohmer JU, Huober J, Rüdiger T, Erbstößer E, Mehta K, Lederer B, Dietel M, Denkert C, von Minckwitz G.
Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study.
Clin Cancer Res. 2015 Aug 15;21(16):3651-7. doi: 10.1158/1078-0432.CCR-14-1283. Epub 2014 Dec 11.

Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration.
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
Mod Pathol. 2015 Sep;28(9):1185-201. doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24.

Dietel M, Jöhrens K, Laffert MV, Hummel M, Bläker H, Pfitzner BM, Lehmann A, Denkert C, Darb-Esfahani S, Lenze D, Heppner FL, Koch A, Sers C, Klauschen F, Anagnostopoulos I.
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Cancer Gene Ther. 2015 Sep;22(9):417-30. doi: 10.1038/cgt.2015.39. Epub 2015 Sep 11. Review.

Sonnenblick A, Brohée S, Fumagalli D, Rothé F, Vincent D, Ignatiadis M, Desmedt C, Salgado R, Sirtaine N, Loi S, Neven P, Loibl S, Denkert C, Joensuu H, Piccart M, Sotiriou C.
Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.
Oncotarget. 2015 Oct 6;6(30):30306-16. doi: 10.18632/oncotarget.5080.

von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marmé F, Potenberg J, Stickeler E, Simon E, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S; German Breast Group Investigators.
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
Cancer. 2015 Oct 15;121(20):3639-48. doi: 10.1002/cncr.29506. Epub 2015 Jun 25.

Loibl S, Schmidt A, Gentilini O, Kaufman B, Kuhl C, Denkert C, von Minckwitz G, Parokonnaya A, Stensheim H, Thomssen C, van Calsteren K, Poortmans P, Berveiller P, Markert UR, Amant F.
Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients.
JAMA Oncol. 2015 Nov;1(8):1145-53. doi: 10.1001/jamaoncol.2015.2413. Erratum in: JAMA Oncol. 2015 Nov;1(8):1172.

Denkert C, Budczies J, von Minckwitz G, Wienert S, Loibl S, Klauschen F.
Strategies for developing Ki67 as a useful biomarker in breast cancer.
Breast. 2015 Nov;24 Suppl 2:S67-72. doi: 10.1016/j.breast.2015.07.017. Epub 2015 Aug 14.

Loibl S, Denkert C, von Minckwitz G.
Neoadjuvant treatment of breast cancer--Clinical and research perspective.
Breast. 2015 Nov;24 Suppl 2:S73-7. doi: 10.1016/j.breast.2015.07.018. Epub 2015 Sep 19.

Publikationen 2014

Loibl S, von Minckwitz G, Untch M, Denkert C; German Breast Group.
Predictive factors for response to neoadjuvant therapy in breast cancer.
Oncol Res Treat. 2014;37(10):563-8. doi: 10.1159/000367643. Epub 2014 Sep 3.

Issa-Nummer Y, Loibl S, von Minckwitz G, Denkert C.
Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy.Oncoimmunology.
2014 Feb 14;3:e27926. eCollection 2014.

Darb-Esfahani S, Sinn BV, Rudl M, Sehouli J, Braicu I, Dietel M, Denkert C.
Interferon-stimulated gene, 15 kDa (ISG15) in ovarian high-grade serous carcinoma: prognostic impact and link to NF-κB pathway.
Int J Gynecol Pathol. 2014 Jan;33(1):16-22. doi: 10.1097/PGP.0b013e31827b25a2.

Arsenic R, Lehmann A, Budczies J, Koch I, Prinzler J, Kleine-Tebbe A, Schewe C, Loibl S, Dietel M, Denkert C.
Analysis of PIK3CA mutations in breast cancer subtypes.
Appl Immunohistochem Mol Morphol. 2014 Jan;22(1):50-6.

von Minckwitz G, Rezai M, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Blohmer JU, Costa SD, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Untch M.
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
Ann Oncol. 2014 Jan;25(1):81-9. doi: 10.1093/annonc/mdt410. Epub 2013 Nov 21.

Loibl S, Volz C, Mau C, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Hanusch C, Jackisch C, Kümmel S, Huober J, Denkert C, Hilfrich J, Konecny GE, Fett W, Stickeler E, Harbeck N, Mehta KM, Nekljudova V, von Minckwitz G, Untch M.
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma.
Breast Cancer Res Treat. 2014 Feb;144(1):153-62. doi: 10.1007/s10549-014-2861-6. Epub 2014 Feb 7.

Denkert C, von Minckwitz G.
Reply to Ki67 in breast cancer: a useful prognostic marker!
Ann Oncol. 2014 Feb;25(2):542-3. doi: 10.1093/annonc/mdt564. Epub 2014 Jan 15. No abstract available.

Aust S, Auer K, Bachmayr-Heyda A, Denkert C, Sehouli J, Braicu I, Mahner S, Lambrechts S, Vergote I, Grimm C, Horvat R, Castillo-Tong DC, Zeillinger R, Pils D.
Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.
Mol Cancer. 2014 Mar 21;13:67. doi: 10.1186/1476-4598-13-67.

Hilvo M, Gade S, Hyötyläinen T, Nekljudova V, Seppänen-Laakso T, Sysi-Aho M, Untch M, Huober J, von Minckwitz G, Denkert C, Orešič M, Loibl S.
Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients.
Int J Cancer. 2014 Apr 1;134(7):1725-33. doi: 10.1002/ijc.28491. Epub 2013 Oct 8.

Fischer K, von Brünneck AC, Hornung D, Denkert C, Ufer C, Schiebel H, Kuhn H, Borchert A.
Differential expression of secretoglobins in normal ovary and in ovarian carcinoma--overexpression of mammaglobin-1 is linked to tumor progression.
Arch Biochem Biophys. 2014 Apr 1;547:27-36. doi: 10.1016/j.abb.2014.02.012. Epub 2014 Mar 3.

Sinn BV, Striefler JK, Rudl MA, Lehmann A, Bahra M, Denkert C, Sinn M, Stieler J, Klauschen F, Budczies J, Weichert W, Stenzinger A, Kamphues C, Dietel M, Riess H.
KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.Pancreas.
2014 May;43(4):578-83. doi: 10.1097/MPA.0000000000000077.

Sinn M, Sinn BV, Striefler JK, Lindner JL, Stieler JM, Lohneis P, Bischoff S, Bläker H, Pelzer U, Bahra M, Dietel M, Dörken B, Oettle H, Riess H, Denkert C.
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.
Ann Oncol. 2014 May;25(5):1025-32. doi: 10.1093/annonc/mdu084. Epub 2014 Feb 20.

von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kümmel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M.
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Lancet Oncol. 2014 Jun;15(7):747-56. doi: 10.1016/S1470-2045(14)70160-3. Epub 2014 Apr 30.

Budczies J, von Winterfeld M, Klauschen F, Kimmritz AC, Daniel JM, Warth A, Endris V, Denkert C, Pfeiffer H, Weichert W, Dietel M, Wittschieber D, Stenzinger A.
Comprehensive analysis of clinico-pathological data reveals heterogeneous relations between atherosclerosis and cancer.
J Clin Pathol. 2014 Jun;67(6):482-90. doi: 10.1136/jclinpath-2013-202148. Epub 2014 Feb 11.

Pfitzner BM, Branstetter D, Loibl S, Denkert C, Lederer B, Schmitt WD, Dombrowski F, Werner M, Rüdiger T, Dougall WC, von Minckwitz G.
RANK expression as a prognostic and predictive marker in breast cancer.
Breast Cancer Res Treat. 2014 Jun;145(2):307-15. doi: 10.1007/s10549-014-2955-1. Epub 2014 Apr 16.

Woopen H, Pietzner K, Richter R, Fotopoulou C, Joens T, Braicu EI, Mellstedt H, Mahner S, Lindhofer H, Darb-Esfahani S, Denkert C, Sehouli J.
Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
J Gynecol Oncol. 2014 Jul;25(3):221-8. doi: 10.3802/jgo.2014.25.3.221. Epub 2014 Jul 3.

Darb-Esfahani S, von Minckwitz G, Denkert C, Ataseven B, Högel B, Mehta K, Kaltenecker G, Rüdiger T, Pfitzner B, Kittel K, Fiedler B, Baumann K, Moll R, Dietel M, Eidtmann H, Thomssen C, Loibl S.
Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes.
BMC Cancer. 2014 Jul 28;14:546. doi: 10.1186/1471-2407-14-546.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C.
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
Ann Oncol. 2014 Aug;25(8):1544-50. doi: 10.1093/annonc/mdu112. Epub 2014 Mar 7.

Denkert C.
The immunogenicity of breast cancer--molecular subtypes matter.
Ann Oncol. 2014 Aug;25(8):1453-5. doi: 10.1093/annonc/mdu235. Epub 2014 Jun 20. No abstract available.

Baccelli I, Stenzinger A, Vogel V, Pfitzner BM, Klein C, Wallwiener M, Scharpff M, Saini M, Holland-Letz T, Sinn HP, Schneeweiss A, Denkert C, Weichert W, Trumpp A.
Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients.
Oncotarget. 2014 Sep 30;5(18):8147-60.

Poremba C, Uhlendorff J, Pfitzner BM, Hennig G, Bohmann K, Bojar H, Krenn V, Brase JC, Haufe F, Averdick M, Dietel M, Kronenwett R, Denkert C.
Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer.
Virchows Arch. 2014 Oct;465(4):409-17. doi: 10.1007/s00428-014-1652-0. Epub 2014 Sep 14.

Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, Sinn P, Khandan F, Eidtmann H, Dohnal K, Heinrichs C, Huober J, Pfitzner B, Fasching PA, Andre F, Lindner JL, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Denkert C.
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
J Clin Oncol. 2014 Oct 10;32(29):3212-20. doi: 10.1200/JCO.2014.55.7876. Epub 2014 Sep 8.

Kriegsmann M, Endris V, Wolf T, Pfarr N, Stenzinger A, Loibl S, Denkert C, Schneeweiss A, Budczies J, Sinn P, Weichert W.
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.
Oncotarget. 2014 Oct 30;5(20):9952-65.

Sinn M, Denkert C, Striefler JK, Pelzer U, Stieler JM, Bahra M, Lohneis P, Dörken B, Oettle H, Riess H, Sinn BV.
α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study.Br J Cancer.
2014 Nov 11;111(10):1917-23. doi: 10.1038/bjc.2014.495. Epub 2014 Oct 14

Heim D, Budczies J, Stenzinger A, Treue D, Hufnagl P, Denkert C, Dietel M, Klauschen F.
Cancer beyond organ and tissue specificity: next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers.
Int J Cancer. 2014 Nov 15;135(10):2362-9. doi: 10.1002/ijc.28882. Epub 2014 Apr 17.

Pénzváltó Z, Lánczky A, Lénárt J, Meggyesházi N, Krenács T, Szoboszlai N, Denkert C, Pete I, Győrffy B.
MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
BMC Cancer. 2014 Nov 18;14:837. doi: 10.1186/1471-2407-14-837.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S; International TILs Working Group 2014.
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
Ann Oncol. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11.

Publikationen 2013

Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, Sinn BV, Ulmer HU, Kronenwett R, Just M, Kühn T, Diebold K, Untch M, Holms F, Blohmer JU, Habeck JO, Dietel M, Overkamp F, Krabisch P, von Minckwitz G, Denkert C.
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.
PLoS One. 2013 Dec 2;8(12):e79775. doi: 10.1371/journal.pone.0079775. eCollection 2013.


Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S.
Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.
Clin Cancer Res. 2013 Jan 1;19(1):28-33. doi: 10.1158/1078-0432.CCR-11-2701. Epub 2012 Dec 20. Review.

Denkert C, Huober J, Loibl S, Prinzler J, Kronenwett R, Darb-Esfahani S, Brase JC, Solbach C, Mehta K, Fasching PA, Sinn BV, Engels K, Reinisch M, Hansmann ML, Tesch H, von Minckwitz G, Untch M.
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer.
Breast Cancer Res. 2013 Feb 7;15(1):R11. doi: 10.1186/bcr3384.

Wienert S, Heim D, Kotani M, Lindequist B, Stenzinger A, Ishii M, Hufnagl P, Beil M, Dietel M, Denkert C, Klauschen F.
CognitionMaster: an object-based image analysis framework.
Diagn Pathol. 2013 Feb 27;8:34. doi: 10.1186/1746-1596-8-34

Denkert C.
Diagnostic and therapeutic implications of tumor-infiltrating lymphocytes in breast cancer.
J Clin Oncol. 2013 Mar 1;31(7):836-7. doi: 10.1200/JCO.2012.47.1698. Epub 2013 Jan 22. No abstract available.

Denkert C, Loibl S, Kronenwett R, Budczies J, von Törne C, Nekljudova V, Darb-Esfahani S, Solbach C, Sinn BV, Petry C, Müller BM, Hilfrich J, Altmann G, Staebler A, Roth C, Ataseven B, Kirchner T, Dietel M, Untch M, von Minckwitz G.
RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.
Ann Oncol. 2013 Mar;24(3):632-9. doi: 10.1093/annonc/mds339. Epub 2012 Nov 6.

Dietel M, Jöhrens K, Laffert M, Hummel M, Bläker H, Müller BM, Lehmann A, Denkert C, Heppner FL, Koch A, Sers C, Anagnostopoulos I.
Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Cancer Gene Ther. 2013 Apr;20(4):211-21. doi: 10.1038/cgt.2013.13. Epub 2013 Mar 15. Review.


Nassir M, Darb-Esfahani S, Richter R, Chekerov R, Hall C, Muallem MZ, Denkert C, Stamatian F, Fotopoulou C, Sehouli J, Braicu EI.
HE4 tissue expression in borderline ovarian tumors: a pilot study by the tumorbank ovarian cancer network.
Anticancer Res. 2013 Apr;33(4):1673-7.

Müller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J, Winzer KJ, Dietel M, Weichert W, Denkert C.
Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.
BMC Cancer. 2013 Apr 30;13:215. doi: 10.1186/1471-2407-13-215.

Taube ET, Frangini S, Caselitz J, Chiantera V, Pahl S, Vercellino GF, Ullrich A, von Cotta G, Dietel M, Younes S, Denkert C.
Ligneous cervicitis in a woman with plasminogen deficiency associated with an atypical form of microglandular hyperplasia: a case report and review of literature.
Int J Gynecol Pathol. 2013 May;32(3):329-34. doi: 10.1097/PGP.0b013e3182625fec. Review.

Pietzner K, Woopen H, Richter R, Joens T, Braicu EI, Dimitrova D, Mellstedt H, Darb-Esfahani S, Denkert C, Lindhofer H, Fotopoulou C, Sehouli J.
Expression of epithelial cell adhesion molecule in paired tumor samples of patients with primary and recurrent serous ovarian cancer.
Int J Gynecol Cancer. 2013 Jun;23(5):797-802. doi: 10.1097/IGC.0b013e3182929056.

Karle J, Bolbrinker J, Vogl S, Kreutz R, Denkert C, Eucker J, Wischnewsky M, Possinger K, Regierer AC.
Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.
Breast Cancer Res Treat. 2013 Jun;139(2):553-60. doi: 10.1007/s10549-013-2565-3. Epub 2013 May 18.

Müller BM, Keil E, Lehmann A, Winzer KJ, Richter-Ehrenstein C, Prinzler J, Bangemann N, Reles A, Stadie S, Schoenegg W, Eucker J, Schmidt M, Lippek F, Jöhrens K, Pahl S, Sinn BV, Budczies J, Dietel M, Denkert C.
The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions.
PLoS One. 2013 Jun 27;8(6):e68252. Print 2013.

Liebscher CA, Prinzler J, Sinn BV, Budczies J, Denkert C, Noske A, Sehouli J, Braicu EI, Dietel M, Darb-Esfahani S.
Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Hum Pathol. 2013 Aug;44(8):1465-71. doi: 10.1016/j.humpath.2012.12.016. Epub 2013 Mar 1.

von Minckwitz G, Schmitt WD, Loibl S, Müller BM, Blohmer JU, Sinn BV, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Rüdiger T, Erbstoesser E, Fasching PA, Karn T, Müller V, Jackisch C, Denkert C.
Ki67 measured after neoadjuvant chemotherapy for primary breast cancer.
Clin Cancer Res. 2013 Aug 15;19(16):4521-31. doi: 10.1158/1078-0432.CCR-12-3628. Epub 2013 Jun 27.

Bockmayr M, Klauschen F, Györffy B, Denkert C, Budczies J.
New network topology approaches reveal differential correlation patterns in breast cancer.
BMC Syst Biol. 2013 Aug 15;7:78. doi: 10.1186/1752-0509-7-78.

Denkert C, Erbersdobler A, Kellner U, Kristiansen G, Lage H, Petersen I, Röcken C, Stenzinger A, Turzynski A, Weichert W.
[Congratulations on your birthday, dear Mr. Dietel!].
Pathologe. 2013 Sep;34(5):389-90. doi: 10.1007/s00292-013-1780-3. German. No abstract available.

Denkert C.
[Gene expression analysis in breast cancer. A new diagnostic tool in pathology].
Pathologe. 2013 Sep;34(5):413-8. doi: 10.1007/s00292-013-1781-2. Review. German.

Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G, Belau A, Thommsen C, Holzhausen HJ, Grasshoff ST, Baumann K, Mehta K, Dietel M, Loibl S.
Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer.
Ann Oncol. 2013 Sep;24(9):2316-24. doi: 10.1093/annonc/mdt162. Epub 2013 May 9.

Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, Horvat R, Denkert C, Zeillinger R, Castillo-Tong DC.
Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium.
BMC Cancer. 2013 Sep 17;13:422. doi: 10.1186/1471-2407-13-422.

Ruckhäberle E, Karn T, Denkert C, Loibl S, Ataseven B, Reimer T, Becker S, Holtrich U, Rody A, Darb-Esfahani S, Nekljudova V, von Minckwitz G.
Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer.
J Cancer Res Clin Oncol. 2013 Oct;139(10):1681-9. doi: 10.1007/s00432-013-1490-5. Epub 2013 Aug 18.

von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Kümmel S, Paepke S, Schneeweiss A, Untch M, Zahm DM, Mehta K, Loibl S.
Response-guided neoadjuvant chemotherapy for breast cancer.
J Clin Oncol. 2013 Oct 10;31(29):3623-30. doi: 10.1200/JCO.2012.45.0940. Epub 2013 Sep 3.

Sinn M, Striefler JK, Sinn BV, Sallmon D, Bischoff S, Stieler JM, Pelzer U, Bahra M, Neuhaus P, Dörken B, Denkert C, Riess H, Oettle H.
Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study.
J Surg Oncol. 2013 Nov;108(6):398-402. doi: 10.1002/jso.23409. Epub 2013 Aug 23.

Denkert C, Loibl S, Müller BM, Eidtmann H, Schmitt WD, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Erbstösser E, Blohmer JU, Budczies J, Mehta KM, von Minckwitz G.
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
Ann Oncol. 2013 Nov;24(11):2786-93. doi: 10.1093/annonc/mdt350. Epub 2013 Aug 22.

Budczies J, Brockmöller SF, Müller BM, Barupal DK, Richter-Ehrenstein C, Kleine-Tebbe A, Griffin JL, Orešič M, Dietel M, Denkert C, Fiehn O.
Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism.
J Proteomics. 2013 Dec 6;94:279-88. doi: 10.1016/j.jprot.2013.10.002. Epub 2013 Oct 11.

Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S.
Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.
Clin Cancer Res. 2013 Jan 1;19(1):28-33. doi: 10.1158/1078-0432.CCR-11-2701. Epub 2012 Dec 20. Review.

Denkert C, Loibl S, Kronenwett R, Budczies J, von Törne C, Nekljudova V, Darb-Esfahani S, Solbach C, Sinn BV, Petry C, Müller BM, Hilfrich J, Altmann G, Staebler A, Roth C, Ataseven B, Kirchner T, Dietel M, Untch M, von Minckwitz G.
RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.
Ann Oncol. 2013 Mar;24(3):632-9. doi: 10.1093/annonc/mds339. Epub 2012 Nov 6.

Publikationen 2012

Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, Denkert C.
Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization.
PLoS One. 2012;7(12):e51862. doi: 10.1371/journal.pone.0051862. Epub 2012 Dec 14.

Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, Van de Vijver M, Viale G, Loi S, Reis-Filho JS.
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.
Ann Oncol. 2012 Dec;23(12):2997-3006. doi: 10.1093/annonc/mds586. Review.

Darb-Esfahani S, Kronenwett R, von Minckwitz G, Denkert C, Gehrmann M, Rody A, Budczies J, Brase JC, Mehta MK, Bojar H, Ataseven B, Karn T, Weiss E, Zahm DM, Khandan F, Dietel M, Loibl S.
Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.
Br J Cancer. 2012 Nov 20;107(11):1892-900. doi: 10.1038/bjc.2012.475. Epub 2012 Oct 18.

Wenners AS, Mehta K, Loibl S, Park H, Mueller B, Arnold N, Hamann S, Weimer J, Ataseven B, Darb-Esfahani S, Schem C, Mundhenke C, Khandan F, Thomssen C, Jonat W, Holzhausen HJ, von Minckwitz G, Denkert C, Bauer M.
Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer.
PLoS One. 2012;7(10):e45826. doi: 10.1371/journal.pone.0045826. Epub 2012 Oct 9.

Kronenwett R, Bohmann K, Prinzler J, Sinn BV, Haufe F, Roth C, Averdick M, Ropers T, Windbergs C, Brase JC, Weber KE, Fisch K, Müller BM, Schmidt M, Filipits M, Dubsky P, Petry C, Dietel M, Denkert C.
Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test.
BMC Cancer. 2012 Oct 5;12:456. doi: 10.1186/1471-2407-12-456.

Jerby L, Wolf L, Denkert C, Stein GY, Hilvo M, Oresic M, Geiger T, Ruppin E.
Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer.
Cancer Res. 2012 Nov 15;72(22):5712-20. doi: 10.1158/0008-5472.CAN-12-2215. Epub 2012 Sep 17.

Aust S, Bachmayr-Heyda A, Pateisky P, Tong D, Darb-Esfahani S, Denkert C, Chekerov R, Sehouli J, Mahner S, Van Gorp T, Vergote I, Speiser P, Horvat R, Zeillinger R, Pils D.
Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium.
Mol Cancer. 2012 Sep 14;11:69. doi: 10.1186/1476-4598-11-69.

Klauke ML, Hoogerbrugge N, Budczies J, Bult P, Prinzler J, Radke C, van Krieken JH, Dietel M, Denkert C, Müller BM.
Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer.
Virchows Arch. 2012 Oct;461(4):425-31. doi: 10.1007/s00428-012-1311-2. Epub 2012 Sep 12.

Winzer KJ, Gruber C, Badakhshi H, Hinkelbein M, Denkert C.
[Compliance of patients concerning recommended radiotherapy in breast cancer : Association with recurrence, age, and hormonal therapy].
Strahlenther Onkol. 2012 Sep;188(9):788-94. doi: 10.1007/s00066-012-0153-9. Epub 2012 Aug 5. German.

Budczies J, Denkert C, Müller BM, Brockmöller SF, Klauschen F, Györffy B, Dietel M, Richter-Ehrenstein C, Marten U, Salek RM, Griffin JL, Hilvo M, Orešič M, Wohlgemuth G, Fiehn O.
Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics study.
BMC Genomics. 2012 Jul 23;13:334. doi: 10.1186/1471-2164-13-334.

Wienert S, Heim D, Saeger K, Stenzinger A, Beil M, Hufnagl P, Dietel M, Denkert C, Klauschen F.
Detection and segmentation of cell nuclei in virtual microscopy images: a minimum-model approach.
Sci Rep. 2012;2:503. doi: 10.1038/srep00503. Epub 2012 Jul 11.

Darb-Esfahani S, Fritzsche F, Kristiansen G, Weichert W, Sehouli J, Braicu I, Dietel M, Denkert C.
Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
Virchows Arch. 2012 Aug;461(2):109-16. doi: 10.1007/s00428-012-1273-4. Epub 2012 Jul 3.

Faggad A, Kasajima A, Weichert W, Stenzinger A, Elwali NE, Dietel M, Denkert C.
Down-regulation of the microRNA processing enzyme Dicer is a prognostic factor in human colorectal cancer.
Histopathology. 2012 Oct;61(4):552-61. doi: 10.1111/j.1365-2559.2011.04110.x.

Wittschieber D, Klauschen F, Kimmritz AC, von Winterfeld M, Kamphues C, Scholman HJ, Erbersdobler A, Pfeiffer H, Denkert C, Dietel M, Weichert W, Budczies J, Stenzinger A.
Who is at risk for diagnostic discrepancies? Comparison of pre- and postmortal diagnoses in 1800 patients of 3 medical decades in East and West Berlin.
PLoS One. 2012;7(5):e37460. doi: 10.1371/journal.pone.0037460. Epub 2012 May 22.

Lehmann A, Schewe C, Hennig G, Denkert C, Weichert W, Budczies J, Dietel M.
Applicability of a System for fully automated nucleic acid extraction from formalin-fixed paraffin-embedded sections for routine KRAS mutation testing.
Diagn Mol Pathol. 2012 Jun;21(2):114-9. doi: 10.1097/PDM.0b013e31823569ca.

Denkert C, Bucher E, Hilvo M, Salek R, Orešič M, Griffin J, Brockmöller S, Klauschen F, Loibl S, Barupal DK, Budczies J, Iljin K, Nekljudova V, Fiehn O.
Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery.
Genome Med. 2012 Apr 30;4(4):37.

von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S.
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
J Clin Oncol. 2012 May 20;30(15):1796-804. doi: 10.1200/JCO.2011.38.8595. Epub 2012 Apr 16.

Stenzinger A, von Winterfeld M, Aulmann S, Warth A, Weichert W, Denkert C, Rüschoff J, Dietel M, Klauschen F.
Quantitative analysis of diagnostic guidelines for HER2-status assessment.
J Mol Diagn. 2012 May-Jun;14(3):199-205. doi: 10.1016/j.jmoldx.2012.01.012.

Müller BM, Brase JC, Haufe F, Weber KE, Budzies J, Petry C, Prinzler J, Kronenwett R, Dietel M, Denkert C.
Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections.
J Clin Pathol. 2012 Jul;65(7):660-2. doi: 10.1136/jclinpath-2012-200716. Epub 2012 Mar 23.

Klauschen F, von Winterfeld M, Stenzinger A, Sinn BV, Budczies J, Kamphues C, Bahra M, Wittschieber D, Weichert W, Striefler J, Riess H, Dietel M, Denkert C.
High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer.
Histopathology. 2012 Sep;61(3):409-16. doi: 10.1111/j.1365-2559.2012.04225.x. Epub 2012 Mar 2.

Denkert C, Kronenwett R, Schlake W, Bohmann K, Penzel R, Weber KE, Höfler H, Lehmann U, Schirmacher P, Specht K, Rudas M, Kreipe HH, Schraml P, Schlake G, Bago-Horvath Z, Tiecke F, Varga Z, Moch H, Schmidt M, Prinzler J, Kerjaschki D, Sinn BV, Müller BM, Filipits M, Petry C, Dietel M.
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay.
Virchows Arch. 2012 Mar;460(3):251-9. doi: 10.1007/s00428-012-1204-4. Epub 2012 Feb 28.

von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups.
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
N Engl J Med. 2012 Jan 26;366(4):299-309. doi: 10.1056/NEJMoa1111065.

Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L.
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.
Ann Surg Oncol. 2012 May;19(5):1508-16. doi: 10.1245/s10434-011-2108-2. Epub 2011 Dec 23.

Brockmöller SF, Bucher E, Müller BM, Budczies J, Hilvo M, Griffin JL, Orešič M, Kallioniemi O, Iljin K, Loibl S, Darb-Esfahani S, Sinn BV, Klauschen F, Prinzler J, Bangemann N, Ismaeel F, Fiehn O, Dietel M, Denkert C.
Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling.
J Proteome Res. 2012 Feb 3;11(2):850-60. doi: 10.1021/pr200685r. Epub 2011 Dec 15.

von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C, Holms F, Eidtmann H, Dietrich K, Just M, Clemens MR, Hanusch C, Schrader I, Henschen S, Hoffmann G, Tiemann K, Diebold K, Untch M, Denkert C.
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
Breast Cancer Res Treat. 2012 Apr;132(3):863-70. doi: 10.1007/s10549-011-1621-0. Epub 2011 Jun 12.

Publikationen 2011

Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L.
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.
Ann Surg Oncol. 2012 May;19(5):1508-16. doi: 10.1245/s10434-011-2108-2. Epub 2011 Dec 23.

Denkert C, Sinn BV, Issa Y, Maria Müller B, Maisch A, Untch M, von Minckwitz G, Loibl S.
Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts.
Breast Care (Basel). 2011;6(4):265-272. Epub 2011 Aug 29.

Sinn BV, Darb-Esfahani S, Wirtz RM, Budczies J, Sehouli J, Chekerov R, Dietel M, Denkert C.
Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue.
Histopathology. 2011 Nov;59(5):918-27. doi: 10.1111/j.1365-2559.2011.04028.x.

Brockmöller SF, Bucher E, Müller BM, Budczies J, Hilvo M, Griffin JL, Orešič M, Kallioniemi O, Iljin K, Loibl S, Darb-Esfahani S, Sinn BV, Klauschen F, Prinzler J, Bangemann N, Ismaeel F, Fiehn O, Dietel M, Denkert C.
Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling.
J Proteome Res. 2012 Feb 3;11(2):850-60. doi: 10.1021/pr200685r. Epub 2011 Dec 15.

Braicu EI, Sehouli J, Richter R, Pietzner K, Denkert C, Fotopoulou C.
Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers. 
Br J Cancer. 2011 Dec 6;105(12):1818-24. doi: 10.1038/bjc.2011.455. Epub 2011 Nov 1.

Loibl S, Müller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B, Kulmer U, Alles JU, Mehta K, Denkert C.
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2011 Nov;130(2):477-87. doi: 10.1007/s10549-011-1715-8. Epub 2011 Aug 12.

Noske A, Schwabe M, Weichert W, Darb-Esfahani S, Buckendahl AC, Sehouli J, Braicu EI, Budczies J, Dietel M, Denkert C.
An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. 
BMC Cancer. 2011 Jul 14;11:294. doi: 10.1186/1471-2407-11-294.

Loi S, Symmans WF, Bartlett JM, Fumagalli D, Van't Veer L, Forbes JF, Bedard P, Denkert C, Zujewski J, Viale G, Pusztai L, Esserman LJ, Leyland-Jones BR.
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.
Lancet Oncol. 2011 Nov;12(12):1162-8. doi: 10.1016/S1470-2045(11)70117-6.

Kumari S, Stevens D, Kind T, Denkert C, Fiehn O.
Applying in-silico retention index and mass spectra matching for identification of unknown metabolites in accurate mass GC-TOF mass spectrometry.
Anal Chem. 2011 Aug 1;83(15):5895-902. doi: 10.1021/ac2006137. Epub 2011 Jun 28.

von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C, Holms F, Eidtmann H, Dietrich K, Just M, Clemens MR, Hanusch C, Schrader I, Henschen S, Hoffmann G, Tiemann K, Diebold K, Untch M, Denkert C.
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
Breast Cancer Res Treat. 2012 Apr;132(3):863-70. doi: 10.1007/s10549-011-1621-0. Epub 2011 Jun 12.

Richter-Ehrenstein C, Tombokan F, Fallenberg EM, Schneider A, Denkert C.
Intraductal papillomas of the breast: diagnosis and management of 151 patients.
Breast. 2011 Dec;20(6):501-4. doi: 10.1016/j.breast.2011.05.004. Epub 2011 Jun 2.

von Minckwitz G, Müller BM, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, du Bois A, Zahm DM, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, Denkert C.
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
J Clin Oncol. 2011 Jun 1;29(16):2150-7. doi: 10.1200/JCO.2010.31.9079. Epub 2011 Apr 25.

Denkert C, Darb-Esfahani S, Loibl S, Anagnostopoulos I, Jöhrens K.
Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy.
Semin Immunopathol. 2011 Jul;33(4):341-51. doi: 10.1007/s00281-011-0261-0. Epub 2011 Apr 17. Review.

Hilvo M, Denkert C, Lehtinen L, Müller B, Brockmöller S, Seppänen-Laakso T, Budczies J, Bucher E, Yetukuri L, Castillo S, Berg E, Nygren H, Sysi-Aho M, Griffin JL, Fiehn O, Loibl S, Richter-Ehrenstein C, Radke C, Hyötyläinen T, Kallioniemi O, Iljin K, Oresic M.
Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression.
Cancer Res. 2011 May 1;71(9):3236-45. doi: 10.1158/0008-5472.CAN-10-3894. Epub 2011 Mar 17.

Budczies J, Weichert W, Noske A, Müller BM, Weller C, Wittenberger T, Hofmann HP, Dietel M, Denkert C, Gekeler V.
Genome-wide gene expression profiling of formalin-fixed paraffin-embedded breast cancer core biopsies using microarrays.
J Histochem Cytochem. 2011 Feb;59(2):146-57. doi: 10.1369/jhc.2010.956607.

Müller BM, Kronenwett R, Hennig G, Euting H, Weber K, Bohmann K, Weichert W, Altmann G, Roth C, Winzer KJ, Kristiansen G, Petry C, Dietel M, Denkert C.
Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer.
Diagn Mol Pathol. 2011 Mar;20(1):1-10. doi: 10.1097/PDM.0b013e3181e3630c.

Buckendahl AC, Budczies J, Fiehn O, Darb-Esfahani S, Kind T, Noske A, Weichert W, Sehouli J, Braicu E, Dietel M, Denkert C.
Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics.
Oncol Rep. 2011 Apr;25(4):1005-12. doi: 10.3892/or.2011.1162. Epub 2011 Jan 25.

Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Müller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, Hoffmann G, Heinrich G, Grasshoff ST, Ulmer HU, Denkert C, von Minckwitz G.
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
Breast Cancer Res Treat. 2011 Feb;126(1):109-17. doi: 10.1007/s10549-010-1316-y. Epub 2010 Dec 29.

Kasajima A, Pavel M, Darb-Esfahani S, Noske A, Stenzinger A, Sasano H, Dietel M, Denkert C, Röcken C, Wiedenmann B, Weichert W.
mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.
Endocr Relat Cancer. 2011 Jan 13;18(1):181-92. doi: 10.1677/ERC-10-0126. Print 2011 Feb.

Publikationen 2010

Ingold B., Simon E., Ungethüm U., Kuban R.J., Müller B.M., Lupp A., Neumann U., Ebert M.P.A., Denkert C., Weichert W., Schulz S. & Röcken C.:
Vascular CXCR4 expression - a novel antiangiogenic target in gastric cancer?
PLoS ONE: 5(4) e10087, Jahr:"2010"

Noske A., Pahl S., Fallenberg E., Richter-Ehrenstein C., Buckendahl A.C., Weichert W., Schneider A., Dietel M. & Denkert C.:
Flat epithelial atypia is a common subtype of B3 breast lesions and is associated with noninvasive cancer but not with invasive cancer in final excision histology.
Hum Pathol: 41(4) 522-7, Jahr:"2010"

Weichert W., Schewe C., Lehmann A., Sers C., Denkert C., Budczies J., Stenzinger A., Joos H., Landt O., Heiser V., Röcken C. & Dietel M.:
KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.
J Mol Diagn: 12(1) 35-42, Jahr:"2010"

Publikationen 2009

Publikationen 2008

Fotopoulou C., Sehouli J., Schefold J.C., Wolf C., Denkert C., Lichtenegger W. & Henrich W.:
Preoperative transvaginal ultrasound (TVS) in the description of pelvic tumor spread in endometrial cancer: results of a prospective study.
Anticancer Res: 28(4C) 2453-8, Jahr:"2008"; 1,414 Impact Punkte

Kummel S., Heidecke H., Brock B., Denkert C., Hecktor J., Koninger A., Becker I., Sehouli J., Thomas A., Blohmer J.U., Lichtenegger W. & Kimmig R.:
[Imatinib--a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study]
Gynakol Geburtshilfliche Rundsch: 48(2) 94-100, Jahr:"2008"; 0 Impact Punkte

Niesporek S., Kristiansen G., Thoma A., Weichert W., Noske A., Buckendahl A.C., Jung K., Stephan C., Dietel M. & Denkert C.:
Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression.
Int J Oncol: 32(2) 341-7, Jahr:"2008"; 2,295 Impact Punkte

Noske A., Weichert W., Niesporek S., Röske A., Buckendahl A.C., Koch I., Sehouli J., Dietel M. & Denkert C.:
Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.
Cancer: 112(8) 1733-43, Jahr:"2008"; 4,632 Impact Punkte

Weichert W., Denkert C., Noske A., Darb-Esfahani S., Dietel M., Kalloger S.E., Huntsman D.G. & Köbel M.:
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas.
Neoplasia: 10(9) 1021-7, Jahr:"2008"; 5,674 Impact Punkte

Weichert W., Röske A., Gekeler V., Beckers T., Ebert M.P., Pross M., Dietel M., Denkert C. & Röcken C.:
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.
Lancet Oncol: 9(2) 139-48, Jahr:"2008"; 12,247 Impact Punkte

Weichert W., Röske A., Gekeler V., Beckers T., Stephan C., Jung K., Fritzsche F.R., Niesporek S., Denkert C., Dietel M. & Kristiansen G.:
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.
Brit J Cancer: 98(3) 604-10, Jahr:"2008"; 4,635 Impact Punkte

Weichert W., Röske A., Niesporek S., Noske A., Buckendahl A.C., Dietel M., Gekeler V., Boehm M., Beckers T. & Denkert C.:
Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Clin Cancer Res: 14(6) 1669-77, Jahr:"2008"; 6,25 Impact Punkte

Bernhardt W.M., Wiesener M.S., Weidemann A., Schmitt R., Weichert W., Lechler P., Campean V., Ong A.C., Willam C., Gretz N. & Eckardt K.U.:
Involvement of hypoxia-inducible transcription factors in polycystic kidney disease.
Am J Pathol: 170(3) 830-42, Jahr:"2007"; 5,487 Impact Punkte

Fritzsche F.R., Dietel M., Weichert W. & Buckendahl A.C.:
Cut-resistant protective gloves in pathology--effective and cost-effective.
Virchows Arch: 452(3) 313-8, Jahr:"2008"; 2,029 Impact Punkte

Gu P., Xing X., Tänzer M., Röcken C., Weichert W., Ivanauskas A., Pross M., Peitz U., Malfertheiner P., Schmid R.M. & Ebert M.P.:
Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas.
Neoplasia: 10(6) 563-72, Jahr:"2008"; 5,674 Impact Punkte

Kroencke T.J., Scheurig C., Lampmann L.E., Boekkooi P.F., Kissner L., Kluner C., Weichert W., Hamm B. & Lohle P.N.:
Acrylamido polyvinyl alcohol microspheres for uterine artery embolization: 12-month clinical and MR imaging results.
J Vasc Interv Radiol: 19(1) 47-57, Jahr:"2008"; 2,207 Impact Punkte

Ott S.J., Kühbacher T., Musfeldt M., Rosenstiel P., Hellmig S., Rehman A., Drews O., Weichert W., Timmis K.N. & Schreiber S.:
Fungi and inflammatory bowel diseases: Alterations of composition and diversity.
Scand J Gastroenterol: 43(7) 831-41, Jahr:"2008"; 0 Impact Punkte

Thelen A., Scholz A., Benckert C., Weichert W., Dietz E., Wiedenmann B., Neuhaus P. & Jonas S.:
Tumor-associated lymphangiogenesis correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma.
Ann Surg Oncol: - -, Jahr:"2008"; 3,917 Impact Punkte

Noske A., Schwabe M., Pahl S., Fallenberg E., Richter-Ehrenstein C., Dietel M. & Kristiansen G.:
Report of a metaplastic carcinoma of the breast with multi-directional differentiation: an adenoid cystic carcinoma, a spindle cell carcinoma and melanoma.
Virchows Arch: 452(5) 575-9, Jahr:"2008"; 2,029 Impact Punkte

Pietzner K., Noske A., Cho C.H., Kiecker F. & Sehouli J.:
Amelanotic metastasis of melanoma mimicking ovarian cancer: a case report and review of the literature.

Malek A., Bakhidze E., Noske A., Sers C., Aigner A., Schäfer R. & Tchernitsa O.:
HMGA2 gene is a promising target for ovarian cancer silencing therapy.
Int J Cancer: 123(2) 348-56, Jahr:"2008"; 4,555 Impact Punkte

Publikationen 2007

Chekerov R., Denkert C., Boehmer D., Suesse A., Widing A., Ruhmland B., Giese A., Mustea A., Lichtenegger W. & Sehouli J.:
Online tumor conference in the clinical management of gynecological cancer: experience from a pilot study in Germany.
Int J Gynecol Cancer: - -, Jahr:"2007"; 1,425 Impact Punkte

Denkert C., Thoma A., Niesporek S., Weichert W., Koch I., Noske A., Schicktanz H., Burkhardt M., Jung K., Dietel M. & Kristiansen G.:
Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1.
Prostate: 67(4) 361-9, Jahr:"2007"; 3,674 Impact Punkte

Henrich W., Fotopoulou C., Fuchs I., Wolf C., Schmider A., Denkert C., Lichtenegger W. & Sehouli J.:
Value of preoperative transvaginal sonography (TVS) in the description of tumor pattern in ovarian cancer patients: results of a prospective study.
Anticancer Res: 27(6C) 4289-94, Jahr:"2007"; 1,414 Impact Punkte

Kaufmann M., von Minckwitz G., Bear H.D., Buzdar A., McGale P., Bonnefoi H., Colleoni M., Denkert C., Eiermann W., Jackesz R., Makris A., Miller W., Pierga J.Y., Semiglazov V., Schneeweiss A., Souchon R., Stearns V., Untch M. & Loibl S.:
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.
Ann Oncol: 18(12) 1927-34, Jahr:"2007"; 4,875 Impact Punkte

Koensgen D., Mustea A., Klaman I., Sun P., Zafrakas M., Lichtenegger W., Denkert C., Dahl E. & Sehouli J.:
Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
Gynecol Oncol: - -, Jahr:"2007"; 2,614 Impact Punkte

Lage H. & Denkert C.:
Resistance to chemotherapy in ovarian carcinoma.
Recent Results Cancer Res: 176 51-60, Jahr:"2007"; 0 Impact Punkte

Niesporek S., Weichert W., Sinn B., Röske A., Noske A., Buckendahl A.C., Wirtz R., Sehouli J., Koensgen D., Dietel M. & Denkert C.:
[NF-kappaB subunit p65/RelA expression in ovarian carcinoma: prognostic impact and link to COX-2 overexpression]
Verh Dtsch Ges Pathol: 91 243-9, Jahr:"2007"; 0 Impact Punkte

Weichert W., Boehm M., Gekeler V., Bahra M., Langrehr J., Neuhaus P., Denkert C., Imre G., Weller C., Hofmann H.P., Niesporek S., Jacob J., Dietel M., Scheidereit C. & Kristiansen G.:
High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis.
Brit J Cancer: - -, Jahr:"2007"; 4,635 Impact Punkte

Bernhardt W.M., Wiesener M.S., Weidemann A., Schmitt R., Weichert W., Lechler P., Campean V., Ong A.C., Willam C., Gretz N. & Eckardt K.U.:
Involvement of hypoxia-inducible transcription factors in polycystic kidney disease.
Am J Pathol: 170(3) 830-42, Jahr:"2007"; 5,487 Impact Punkte

Publikationen 2006

Buckendahl A.C., Martens F., Scholman H.J., Denkert C., Dietel M. & Weichert W.:
Acute myocardial infarction caused by coronary tumor thromboembolism: a rare primary manifestation of malignant tumor disease.
Hum Pathol: 37(2) 236-8, Jahr:"2006"; 2,81 Impact Punkte

Burkhardt M., Mayordomo E., Winzer K.J., Fritzsche F., Gansukh T., Pahl S., Weichert W., Denkert C., Guski H., Dietel M. & Kristiansen G.:
Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer.
J Clin Pathol: - -, Jahr:"2006"; 2,245 Impact Punkte

Denkert C., Budczies J., Kind T., Weichert W., Tablack P., Sehouli J., Niesporek S., Könsgen D., Dietel M. & Fiehn O.:
Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors.
Cancer Res: 66(22) 10795-804, Jahr:"2006"; 7,656 Impact Punkte

Denkert C., Koch I., von Keyserlingk N., Noske A., Niesporek S., Dietel M. & Weichert W.:
Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2.
Modern Pathol: - -, Jahr:"2006"; 3,753 Impact Punkte

Denkert C., Schickling O. & von Minckwitz G.:
[Preoperative chemotherapy in breast cancer and the development of new predictive markers]
Verh Dtsch Ges Pathol: 90 114-23, Jahr:"2006"; 0 Impact Punkte

Fritzsche F., Gansukh T., Borgoño C.A., Burkhardt M., Pahl S., Mayordomo E., Winzer K.J., Weichert W., Denkert C., Jung K., Stephan C., Dietel M., Diamandis E.P., Dahl E. & Kristiansen G.:
Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status.
Brit J Cancer: 94(4) 540-547, Jahr:"2006"; 4,459 Impact Punkte

Fritzsche F.R., Dahl E., Pahl S., Burkhardt M., Luo J., Mayordomo E., Gansukh T., Dankof A., Knuechel R., Denkert C., Winzer K.J., Dietel M. & Kristiansen G.:
Prognostic relevance of AGR2 expression in breast cancer.
Clin Cancer Res: 12(6) 1728-34, Jahr:"2006"; 6,177 Impact Punkte

Györffy B., Surowiak P., Kiesslich O., Denkert C., Schäfer R., Dietel M. & Lage H.:
Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations.
Int J Cancer: 118(7) 1699-712, Jahr:"2006"; 4,693 Impact Punkte

Koensgen D., Mustea A., Denkert C., Sun P.M., Lichtenegger W. & Sehouli J.:
Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.
Anticancer Res: 26(2C) 1683-9, Jahr:"2006"; 1,479 Impact Punkte

Noske A., Kaszubiak A., Weichert W., Sers C., Niesporek S., Koch I., Schaefer B., Sehouli J., Dietel M., Lage H. & Denkert C.:
Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.
Cancer Lett: - -, Jahr:"2006"; 3,277 Impact Punkte

Schmider-Ross A., Pirsig O., Gottschalk E., Denkert C., Lichtenegger W. & Reles A.:
Cyclin-dependant kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer.
J Cancer Res Clin: 132(3) 163-70, Jahr:"2006"; 2,469 Impact Punkte

Sehouli J., Stupin J.H., Schlieper U., Kuemmel S., Henrich W., Denkert C., Dietel M. & Lichtenegger W.:
Actinomycotic inflammatory disease and misdiagnosis of ovarian cancer. A case report.
Anticancer Res: 26(2C) 1727-31, Jahr:"2006"; 1,479 Impact Punkte

Sun P., Wei L., Denkert C., Lichtenegger W. & Sehouli J.:
The orphan nuclear receptors, estrogen receptor-related receptors: their role as new biomarkers in gynecological cancer.
Anticancer Res: 26(2C) 1699-706, Jahr:"2006"; 1,479 Impact Punkte

Weichert W., Ullrich A., Schmidt M., Gekeler V., Noske A., Niesporek S., Buckendahl A.C., Dietel M. & Denkert C.:
Expression patterns of polo-like kinase 1 in human gastric cancer.
Cancer Sci: 97(4) 271-6, Jahr:"2006"; 3,869 Impact Punkte

Bernhardt W.M., Schefold J.C., Weichert W., Rudolph B., Frei U., Groneberg D.A. & Schindler R.:
Amelioration of anemia after kidney transplantation in severe secondary oxalosis.
Clin Nephrol: 65(3) 216-21, Jahr:"2006"; 1,418 Impact Punkte

Fritzsche F., Gansukh T., Borgoño C.A., Burkhardt M., Pahl S., Mayordomo E., Winzer K.J., Weichert W., Denkert C., Jung K., Stephan C., Dietel M., Diamandis E.P., Dahl E. & Kristiansen G.:
Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status.
Brit J Cancer: 94(4) 540-547, Jahr:"2006"; 4,459 Impact Punkte

Noske A. & Pahl S.:
Combined adenosquamous and large-cell neuroendocrine carcinoma of the gallbladder.
Virchows Arch: 449(1) 135-6, Jahr:"2006"; 2,251 Impact Punkte

Publikationen 2005

Bhuvarahamurthy V., Schroeder J., Kristiansen G., Roigas J., Denkert C., Johannsen M., Lein M., Loening S.A., Schnorr D., Jung K. & Staack A.:
Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Oncol Rep: 14(3) 777-82, Jahr:"2005"; 1,572 Impact Punkte

Denkert C. & Dietel M.:
Borderline tumors of the ovary and peritoneal implants.
Verh Dtsch Ges Pathol: 89 84-91, Jahr:"2005"; 0 Impact Punkte

Niesporek S., Denkert C., Weichert W., Köbel M., Noske A., Sehouli J., Singer J.W., Dietel M. & Hauptmann S.:
Expression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosis.
Brit J Cancer: 92(9) 1729-36, Jahr:"2005"; 4,115 Impact Punkte

Noske A., Denkert C., Schober H., Sers C., Zhumabayeva B., Weichert W., Dietel M. & Wiechen K.:
Loss of Gelsolin expression in human ovarian carcinomas.
Eur J Cancer: 41(3) 461-9, Jahr:"2005"; 3,706 Impact Punkte

Sun P.M., Wei L.H., Sehouli J., Denkert C., Zhao D., Gao M., Sun X.L. & Litchtenegger W.:
[Role of estrogen receptor-related receptors alpha, beta and gamma in ovarian cancer cells]
Chung Hua Fu Chan Ko Tsa Chih: 40(8) 544-8, Jahr:"2005"; 0 Impact Punkte

Sun P., Sehouli J., Denkert C., Mustea A., Könsgen D., Koch I., Wei L. & Lichtenegger W.:
Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells.
J Mol Med-Jmm: 83(6) 457-467, Jahr:"2005"; 4,702 Impact Punkte

Surowiak P., Materna V., Denkert C., Kaplenko I., Spaczy ski M., Dietel M., Zabel M. & Lage H.:
Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers.
Cancer Lett: - -, Jahr:"2005"; 3,049 Impact Punkte

Surowiak P., Materna V., Matkowski R., Szczuraszek K., Kornafel J., Wojnar A., Pudelko M., Dietel M., Denkert C., Zabel M. & Lage H.:
Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance.
Breast Cancer Res: 7(5) R862-70, Jahr:"2005"; 4,026 Impact Punkte

Weichert W., Denkert C., Burkhardt M., Gansukh T., Bellach J., Altevogt P., Dietel M. & Kristiansen G.:
Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival.
Clin Cancer Res: 11(18) 6574-81, Jahr:"2005"; 5,715 Impact Punkte

Weichert W., Denkert C., Gauruder-Burmester A., Kurzeja R., Hamm B., Dietel M. & Kroencke T.J.:
Uterine arterial embolization with tris-acryl gelatin microspheres: a histopathologic evaluation.
Am J Surg Pathol: 29(7) 955-961, Jahr:"2005"; 4,377 Impact Punkte

Weichert W., Kristiansen G., Schmidt M., Gekeler V., Noske A., Niesporek S., Dietel M. & Denkert C.:
Polo-like kinase 1 expression is a prognostic factor in human colon cancer.
World J Gastroentero: 11(36) 5644-50, Jahr:"2005"; 0 Impact Punkte

Weichert W., Kristiansen G., Winzer K.J., Schmidt M., Gekeler V., Noske A., Müller B.M., Niesporek S., Dietel M. & Denkert C.:
Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications.
Virchows Arch: 446(4) 442-50, Jahr:"2005"; 2,224 Impact Punkte

Weichert W., Schmidt M., Jacob J., Gekeler V., Langrehr J., Neuhaus P., Bahra M., Denkert C., Dietel M. & Kristiansen G.:
Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer.
Pancreatology: 5(2-3) 259-265, Jahr:"2005"; 1,564 Impact Punkte

Schmitt R., Weichert W., Schneider W., Luft F.C. & Kettritz R.:
Pseudo-pseudo Meigs' syndrome.
Lancet: 366(9497) 1672, Jahr:"2005"; 23,407 Impact Punkte

Publikationen 2004

Bhuvarahamurthy V., Schroeder J., Denkert C., Kristiansen G., Schnorr D., Loening S.A., Jung K. & Staack A.:
In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Oncol Rep: 12(4) 909-13, Jahr:"2004"; 1,356 Impact Punkte

Denkert C.:
[Prognostic role and regulation of cyclooxygenase-2 (COX-2) in ovarian carcinoma]
Zentralbl Gynakol: 126(5) 326-7, Jahr:"2004"; 0 Impact Punkte

Denkert C., Weichert W., Pest S., Koch I., Licht D., Köbel M., Reles A., Sehouli J., Dietel M. & Hauptmann S.:
Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression.
Cancer Res: 64(1) 189-95, Jahr:"2004"; 7,69 Impact Punkte

Denkert C., Weichert W., Winzer K.J., Müller B.M., Noske A., Niesporek S., Kristiansen G., Guski H., Dietel M. & Hauptmann S.:
Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma.
Clin Cancer Res: 10(16) 5580-6, Jahr:"2004"; 5,623 Impact Punkte

Denkert C., Winzer K.J. & Hauptmann S.:
Prognostic impact of cyclooxygenase-2 in breast cancer.
Clin Breast Cancer: 4(6) 428-33, Jahr:"2004"; 0 Impact Punkte

Weichert W., Denkert C., Schmidt M., Gekeler V., Wolf G., Köbel M., Dietel M. & Hauptmann S.:
Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma.
Brit J Cancer: 90(4) 815-21, Jahr:"2004"; 3,742 Impact Punkte

Weichert W., Schmidt M., Gekeler V., Denkert C., Stephan C., Jung K., Loening S., Dietel M. & Kristiansen G.:
Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades.
Prostate: 60(3) 240-5, Jahr:"2004"; 4,331 Impact Punkte

Köbel M., Weichert W., Crüwell K., Schmitt W.D., Lautenschläger C. & Hauptmann S.:
Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis.
Virchows Arch: - -, Jahr:"2004"; 2,227 Impact Punkte

Weichert W., Knösel T., Bellach J., Dietel M. & Kristiansen G.:
ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival.
J Clin Pathol: 57(11) 1160-4, Jahr:"2004"; 2,619 Impact Punkte

Publikationen 2003

Denkert C., Fürstenberg A., Daniel P.T., Koch I., Köbel M., Weichert W., Siegert A. & Hauptmann S.:
Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference.
Oncogene: 22(54) 8653-61, Jahr:"2003"; 6,495 Impact Punkte

Denkert C., Koch I., Berger S., Kobel M., Siegert A. & Hauptmann S.:
Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells.
Cancer Lett: 195(1) 101-9., Jahr:"2003"; 2,614 Impact Punkte

Denkert C., Winzer K.J., Muller B.M., Weichert W., Pest S., Kobel M., Kristiansen G., Reles A., Siegert A., Guski H. & Hauptmann S.:
Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma.
Cancer: 97(12) 2978-87., Jahr:"2003"; 4,017 Impact Punkte

Hauptmann S., Budianto D., Denkert C., Kobel M., Borsi L. & Siri A.:
Adhesion and migration of HRT-18 colorectal carcinoma cells on extracellular matrix components typical for the desmoplastic stroma of colorectal adenocarcinomas.
Oncology-Basel: 65(2) 174-81., Jahr:"2003"; 2,381 Impact Punkte

Hauptmann S., Siegert A., Berger S., Denkert C., Kobel M., Ott S., Siri A. & Borsi L.:
Regulation of cell growth and the expression of extracellular matrix proteins in colorectal adenocarcinoma: a fibroblast-tumor cell coculture model to study tumor-host interactions in vitro.
Eur J Cell Biol: 82(1) 1-8., Jahr:"2003"; 2,185 Impact Punkte

Kristiansen G., Schluns K., Yongwei Y., Denkert C., Dietel M. & Petersen I.:
CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients.
Brit J Cancer: 88(2) 231-6., Jahr:"2003"; 3,894 Impact Punkte

Kristiansen G., Winzer K.J., Mayordomo E., Bellach J., Schlüns K., Denkert C., Dahl E., Pilarsky C., Altevogt P., Guski H. & Dietel M.:
CD24 expression is a new prognostic marker in breast cancer.
Clin Cancer Res: 9(13) 4906-13, Jahr:"2003"; 6,511 Impact Punkte

Weichert W., Gekeler V., Denkert C., Dietel M. & Hauptmann S.:
Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis.
Int J Oncol: 23(3) 633-9., Jahr:"2003"; 2,536 Impact Punkte

Publikationen 2002

Denkert C., Kobel M., Pest S., Koch I., Berger S., Schwabe M., Siegert A., Reles A., Klosterhalfen B. & Hauptmann S.:
Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.
Am J Pathol: 160(3) 893-903., Jahr:"2002"; 6,75 Impact Punkte

Denkert C., Schmitt W.D., Berger S., Reles A., Pest S., Siegert A., Lichtenegger W., Dietel M. & Hauptmann S.:
Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma.
Int J Cancer: 102(5) 507-13., Jahr:"2002"; 4,056 Impact Punkte

Denkert C., Siegert A., Leclere A., Turzynski A. & Hauptmann S.:
An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells.
Clin Exp Metastas: 19(1) 79-85., Jahr:"2002"; 2,08 Impact Punkte

Hauptmann S., Denkert C., Koch I., Petersen S., Schluns K., Reles A., Dietel M. & Petersen I.:
Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization.
Hum Pathol: 33(6) 632-41., Jahr:"2002"; 3,049 Impact Punkte

Kristiansen G., Denkert C., Schluns K., Dahl E., Pilarsky C. & Hauptmann S.:
CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival.
Am J Pathol: 161(4) 1215-21., Jahr:"2002"; 6,75 Impact Punkte

Siegert A., Rosenberg C., Schmitt W.D., Denkert C. & Hauptmann S.:
Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumour cell invasion.
Brit J Cancer: 86(8) 1310-5., Jahr:"2002"; 3,639 Impact Punkte

Kruschewski M., Noske A., Haier J., Runkel N., Anagnostopoulos Y. & Buhr H.J.:
Is reduced expression of mismatch repair genes MLH1 and MSH2 in patients with sporadic colorectal cancer related to their prognosis?
Clin Exp Metastas: 19(1) 71-7, Jahr:"2002"; 2,08 Impact Punkte

Publikationen 2001

Berger S., Siegert A., Denkert C., Kobel M. & Hauptmann S.:
Interleukin-10 in serous ovarian carcinoma cell lines.
Cancer Immunol Immun: 50(6) 328-33., Jahr:"2001"; 2,382 Impact Punkte

Denkert C., Kobel M., Berger S., Siegert A., Leclere A., Trefzer U. & Hauptmann S.:
Expression of cyclooxygenase 2 in human malignant melanoma.
Cancer Res: 61(1) 303-8., Jahr:"2001"; 8,302 Impact Punkte

Publikationen 2000

Eucker J., Sezer O., Lehmann R., Weber J.R., Graf B., Denkert C., Bruck W., Schweigert M. & Possinger K.:
Disseminated mucormycosis caused by Absidia corymbifera leading to cerebral vasculitis.
Infection: 28(4) 246-50., Jahr:"2000"; 1,254 Impact Punkte

Publikationen 1999

Siegert A., Denkert C., Leclere A. & Hauptmann S.:
Suppression of the reactive oxygen intermediates production of human macrophages by colorectal adenocarcinoma cell lines.
Immunology: 98(4) 551-6., Jahr:"1999"; 2,575 Impact Punkte

Trefzer U., Schlegel C., Sterry W., Spath-Schwalbe E., Possinger K. & Denkerk C.: Fulminant intravascular disseminating malignant melanoma mimicking acute leukemia [letter] Blood: 94(4) 1483-4, Jahr:"1999"; 8,782 Impact Punkte

Publikationen 1998

Denkert C., Warskulat U., Hensel F. & Häussinger D.:
Osmolyte strategy in human monocytes and macrophages: involvement of p38MAPK in hyperosmotic induction of betaine and myoinositol transporters.
Arch Biochem Biophys: 354 (1) 172-180, Jahr:"1998"; 2,497 Impact Punkte

Hauptmann S., Gebauer-Hartung P., Leclere A., Denkert C., Pest S., Klosterhalfen B. & Dietel M.: Induction of apoptosis in the centre of multicellular tumour spheroids of colorectal adenocarcinomas--involvement of CD95 pathway and differentiation. Apoptosis: 3(4) 267-79, Jahr:"1998"

Publikationen 1995

Hauptmann S., Denkert C., Lohrke H., Tietze L., Ott S., Klosterhalfen B. & Mittermayer C.:
Integrin expression on colorectal tumor cells growing as monolayers, as multicellular tumor spheroids, or in nude mice.
Int J Cancer: 61(6) 819-25, Jahr:"1995"; 3,403 Impact Punkte